NgoJuni 29, 2017, ukuthuthukiswa kweLaipushutai, ikilasi Imithi emisha ngokuthuthuka ngokubambisana kwe-Jmed and Guangzhou LinkHealth Medical Technology Co, Ltd. Isimemezelo se-Indic Drug samukelwe yi-CFDA.

UJymed noGuangzhou LinkHealth Technology Con Technology Co, Ltd. Kufinyelelwe esivumelwaneni sokubambisana ngonyaka we-2016 ukuze kuthuthukiswe lo mkhiqizo eChina. Izinhlobo ziqede izifundo ze-PoC Clinical ku-EU futhi zathola ukuphepha okuhle kanye namanani axolelwe. Kokubili i-FDA ne-EMA bayabona ukuthi le hlobo ingafakwa ekwelashweni ngomugqa we-I / II, futhi izobaluleka kuzonikezwa impumuzo kanye nokwelashwa kweziguli ezine-ulcerative colitis kulo lonke i-ulcerative colitis e-CFDA.

I-Ulcerative Colitis (UC) isifo sokuvuvukala esingamahlalakhona, esingaqondile sokuvuvukala esenzeka eRectum naseColon. Ngokusho kwezibalo, isilinganiso sezehlakalo i-UC singamacala ayi-1,2 kuye kwangama-20 Isigameko se-UC sivame kakhulu kubantu abadala abasebasha. Imakethe ye-UC inezinga elikhulu futhi ifune ukuthola izidakamizwa, futhi izoqhubeka nokugcina umkhuba wokukhula okuphezulu esikhathini esizayo. Kuze kube manje, umuthi wokuqala we-UC Okokuqala usekelwe ikakhulu ku-mesalazine nama-hormone, kanti nemithi yomugqa wesibili ifaka ama-immunosuppression kanye nama-antibodies ezinto eziphilayo. I-MESalazine inevolumu yokuthengisa eyi-1 billion eChina nase-US $ 2 billion e-United States ngonyaka ka-2015. ILaipushutai inokuphendula okungcono ezimpahleni ze-UC, futhi iphephe kakhulu kunezidakamizwa zomugqa wokuqala. Inenzuzo enhle yemakethe futhi kulindeleke ukuba ibe umuthi wokuqala we-UC.